FI964897A0 - Serotonin 5HT1A- och dopamin D2 -receptorligander - Google Patents
Serotonin 5HT1A- och dopamin D2 -receptorliganderInfo
- Publication number
- FI964897A0 FI964897A0 FI964897A FI964897A FI964897A0 FI 964897 A0 FI964897 A0 FI 964897A0 FI 964897 A FI964897 A FI 964897A FI 964897 A FI964897 A FI 964897A FI 964897 A0 FI964897 A0 FI 964897A0
- Authority
- FI
- Finland
- Prior art keywords
- alkyl
- dopamine
- cycloalk
- alkenyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK65794 | 1994-06-08 | ||
PCT/DK1995/000229 WO1995033729A1 (en) | 1994-06-08 | 1995-06-08 | Serotonin 5-ht1a and dopamin d2 receptor ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
FI964897A0 true FI964897A0 (sv) | 1996-12-05 |
FI964897A FI964897A (sv) | 1996-12-05 |
Family
ID=8096051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI964897A FI964897A (sv) | 1994-06-08 | 1996-12-05 | Serotonin 5HT1A- och dopamin D2 -receptorligander |
Country Status (27)
Country | Link |
---|---|
US (2) | US6514993B1 (sv) |
EP (1) | EP0770066B1 (sv) |
JP (1) | JPH10500959A (sv) |
KR (1) | KR100382812B1 (sv) |
CN (1) | CN1067057C (sv) |
AT (1) | ATE193016T1 (sv) |
AU (1) | AU686400B2 (sv) |
BR (1) | BR9507930A (sv) |
CA (1) | CA2192113A1 (sv) |
CZ (1) | CZ287801B6 (sv) |
DE (1) | DE69517027T2 (sv) |
DK (1) | DK0770066T3 (sv) |
ES (1) | ES2148527T3 (sv) |
FI (1) | FI964897A (sv) |
GR (1) | GR3034105T3 (sv) |
HK (1) | HK1000877A1 (sv) |
HU (1) | HUT76470A (sv) |
IL (1) | IL114027A (sv) |
MX (1) | MX9605863A (sv) |
NO (1) | NO308534B1 (sv) |
NZ (1) | NZ288180A (sv) |
PL (1) | PL180847B1 (sv) |
PT (1) | PT770066E (sv) |
RU (1) | RU2140920C1 (sv) |
SK (1) | SK281646B6 (sv) |
WO (1) | WO1995033729A1 (sv) |
ZA (1) | ZA954688B (sv) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159990A (en) | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
US6376494B1 (en) | 1998-06-15 | 2002-04-23 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
JP2002518382A (ja) * | 1998-06-15 | 2002-06-25 | アメリカン・ホーム・プロダクツ・コーポレイション | セロトニン作動薬としてのシクロアルキル−置換アリール−ピペラジン、ピペリジンおよびテトラヒドロピリジン |
GB9912417D0 (en) * | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
FR2803298A1 (fr) * | 1999-12-30 | 2001-07-06 | Adir | Nouvelles urees lineaires ou cycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
UA73981C2 (en) | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
CN1474688A (zh) * | 2000-11-14 | 2004-02-11 | Ĭ��ר���ɷ�����˾ | 联合选择性多巴胺d2受体拮抗剂和5-ht1a受体兴奋剂的新用途 |
HUP0402092A3 (en) | 2001-07-26 | 2010-06-28 | Merck Patent Gmbh | Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions |
WO2003074518A1 (en) * | 2002-03-06 | 2003-09-12 | Merck Patent Gmbh | Thiazole derivatives and their use d2- and 5-ht1a-receptor ligands |
EP1608319A4 (en) | 2003-04-03 | 2007-02-28 | Univ California | IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE |
WO2005089380A2 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
US20040253576A1 (en) * | 2003-04-04 | 2004-12-16 | The Regents Of The University Of California | Modulating cooperative activity of dopamine D1 and D2 receptors to mitigate substance abuse |
WO2006045119A2 (en) * | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
WO2006058294A2 (en) * | 2004-11-29 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
WO2006105035A2 (en) * | 2005-03-28 | 2006-10-05 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
US8422893B2 (en) | 2010-01-21 | 2013-04-16 | Samsung Electronics Co., Ltd | Developer and image forming apparatus including the same |
EP2844346B1 (en) | 2012-04-04 | 2020-01-01 | Prilenia Neurotherapeutics Ltd. | Pharmaceutical compositions for combination therapy |
CN110143947B (zh) * | 2019-05-29 | 2021-10-15 | 华东师范大学 | 一种色瑞替尼类似物的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3374237A (en) * | 1965-05-21 | 1968-03-19 | American Cyanamid Co | 1-phenyl-3-(4-phenyl-1-piperazinoalkyl)-imidazolidinones and imidazolidinethiones |
DE2263211A1 (de) * | 1972-12-23 | 1974-07-04 | Boehringer Sohn Ingelheim | Neue arylpiperazine und verfahren zu ihrer herstellung |
US4452798A (en) * | 1982-06-22 | 1984-06-05 | Warner-Lambert Company | 1-Substituted phenyl-4-alkyl hydantoin piperazine compounds as antihypertensive agents |
WO1990006303A1 (en) * | 1988-12-02 | 1990-06-14 | Pfizer Inc. | Arylpiperidine derivatives |
AU8212491A (en) * | 1990-06-29 | 1992-01-23 | Upjohn Company, The | Substituted 1-(alkoxyphenyl)piperazines with cns and antihypertensive activity |
IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
US5314885A (en) * | 1992-09-11 | 1994-05-24 | Mcneilab, Inc. | Cyclic benzylamino, benzylamido, and benzylimido antipsychotic agents |
ATE161533T1 (de) * | 1993-09-15 | 1998-01-15 | Merck Sharp & Dohme | Imidanolon- und oxanolonderivate als dopaminantagonisten |
US6150367A (en) * | 1997-10-20 | 2000-11-21 | Council Of Scientific & Industrial Research | 1-[4-arylpiperazin-1-yl]-3-[2-oxopyrrolidin/piperidin-1-yl]propanes and their use in medical treatments |
-
1995
- 1995-06-07 IL IL11402795A patent/IL114027A/xx not_active IP Right Cessation
- 1995-06-07 ZA ZA954688A patent/ZA954688B/xx unknown
- 1995-06-08 WO PCT/DK1995/000229 patent/WO1995033729A1/en active IP Right Grant
- 1995-06-08 ES ES95922420T patent/ES2148527T3/es not_active Expired - Lifetime
- 1995-06-08 DE DE69517027T patent/DE69517027T2/de not_active Expired - Fee Related
- 1995-06-08 CN CN95194369A patent/CN1067057C/zh not_active Expired - Fee Related
- 1995-06-08 DK DK95922420T patent/DK0770066T3/da active
- 1995-06-08 HU HU9603372A patent/HUT76470A/hu unknown
- 1995-06-08 SK SK1549-96A patent/SK281646B6/sk unknown
- 1995-06-08 AU AU27322/95A patent/AU686400B2/en not_active Ceased
- 1995-06-08 NZ NZ288180A patent/NZ288180A/en unknown
- 1995-06-08 RU RU97100172A patent/RU2140920C1/ru not_active IP Right Cessation
- 1995-06-08 AT AT95922420T patent/ATE193016T1/de not_active IP Right Cessation
- 1995-06-08 PT PT95922420T patent/PT770066E/pt unknown
- 1995-06-08 KR KR1019960707006A patent/KR100382812B1/ko not_active IP Right Cessation
- 1995-06-08 CZ CZ19963589A patent/CZ287801B6/cs not_active IP Right Cessation
- 1995-06-08 BR BR9507930A patent/BR9507930A/pt not_active Application Discontinuation
- 1995-06-08 EP EP95922420A patent/EP0770066B1/en not_active Expired - Lifetime
- 1995-06-08 CA CA002192113A patent/CA2192113A1/en not_active Abandoned
- 1995-06-08 PL PL95317530A patent/PL180847B1/pl not_active IP Right Cessation
- 1995-06-08 JP JP8500193A patent/JPH10500959A/ja not_active Withdrawn
-
1996
- 1996-11-26 MX MX9605863A patent/MX9605863A/es not_active IP Right Cessation
- 1996-12-04 NO NO965183A patent/NO308534B1/no not_active IP Right Cessation
- 1996-12-05 FI FI964897A patent/FI964897A/sv not_active IP Right Cessation
- 1996-12-09 US US09/424,930 patent/US6514993B1/en not_active Expired - Fee Related
-
1997
- 1997-12-18 HK HK97102506A patent/HK1000877A1/xx not_active IP Right Cessation
-
2000
- 2000-08-02 GR GR20000401802T patent/GR3034105T3/el not_active IP Right Cessation
-
2002
- 2002-12-30 US US10/334,481 patent/US20030120070A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI964897A0 (sv) | Serotonin 5HT1A- och dopamin D2 -receptorligander | |
PL287961A1 (en) | Method of obtaining novel tricyclic compounds | |
AR002986A1 (es) | Nuevos derivados de piperazina sustituida particularmente utiles como antagonistas de receptores de taquiquinina, composiciones farmaceuticas, usosde dichos derivados y procedimiento de preparacion de los mismos. | |
DE69313866D1 (de) | Chinoxalinderivate als eaa antagonisten | |
DE69712325T2 (de) | Verwendung von 4-phenyl-3,6-dihydro-2h-pyridyl derivaten als nmda rezeptor subtyp blocker | |
GB2341799B (en) | Medicaments for the treatment of primary headache disorders and drug-induced headaches | |
ATE134191T1 (de) | N-imidazolylderivate von substituiertem tetrahydrocarbazol und cyclohepta(b>indol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MA | Patent expired |